Showing 4711-4720 of 5000 results for "".
- The Skin Type Solutions® Franchise System Launched by Leslie Baumann, MDhttps://practicaldermatology.com/news/20140625-the_skin_type_solutionsfranchise_system_launched_by_leslie_baumann_md/2459189/The Skin Type Solutions® Franchise model, just introduced by dermatologist Leslie Baumann, MD, is intended to allow every dermatologist to be the primary source of skincare guidance before a patient makes a purchase, and make the proper skincare regimens available right there at the office. Th
- FDA Approves Sivextro to Treat Skin Infections in Adultshttps://practicaldermatology.com/news/20140624-fda_approves_sivextro_to_treat_skin_infections_in_adults/2459192/The FDA approved Sivextro (tedizolid phosphate), a new antibacterial drug, to treat adults with skin infections. Sivextro, which is marketed by Cubist Pharmaceuticals, is approved to treat patients with acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bact
- Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Updatehttps://practicaldermatology.com/news/20140623-verisante_technology_inc_announces_2014_first_quarter_results_and_provides_operational_update/2459195/Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has released its financial results for the first quarter ended March 31, 2014 .
- Valeant Commences Exchange Offer For Allerganhttps://practicaldermatology.com/news/20140618-valeant_commences_exchange_offer_for_allergan/2459200/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30th proposal directly to Allergan stockholders. Under the terms of the offer, Allerg
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perio
- TruInject Injector Training System Receives Approval of Its Patenthttps://practicaldermatology.com/news/20140613-truinject_injector_training_system_receives_approval_of_its_patent/2459207/One of the key patent applications of TruInject Medical Corporation has been allowed by the US Patent Office. The patent is expected to issue shortly. The patent is for a cosmetic and therapeutic injector training system and is one of many pate
- Provectus Biopharmaceuticals will discuss outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Callhttps://practicaldermatology.com/news/20140612-provectus_biopharmaceuticals_will_discuss_outline_of_phase_3_clinical_trial_of_pv-10_to_treat_melanoma_on_conference_call/2459208/Provectus Biopharmaceuticals, Inc. has announced that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time. Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-
- Allergan Again Unanimously Rejects Valeant's Revised Unsolicited Proposalhttps://practicaldermatology.com/news/20140610-allergan_again_unanimously_rejects_valeants_revised_unsolicited_proposal/2459212/Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced Tuesday that its board of directors, after consulting with its independent financial and legal advisors
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw